06/17/2026
Today’s announcement from uniQure marks an encouraging and meaningful step forward for the Huntington’s disease community.
The FDA’s indication that three-year data from the Phase I/II AMT-130 study may serve as the primary basis for a BLA for accelerated approval offers renewed hope to families who have been waiting far too long for treatment options.
This milestone reflects the power of a united HD community — families, advocates, clinicians, partner organizations, and Members of Congress — who helped ensure that the voices of those impacted by HD were heard.
While there is still important work ahead, including the regulatory process and a necessary confirmatory study, today brings hope and momentum.
HDSA remains committed to working with regulators, uniQure, HD sister organizations, clinicians, and the broader healthcare community to help move these next steps forward safely and as expeditiously as possible.
Read HDSA’s full statement: https://hdsa.org/news/hdsa-statement-on-uniqures-amt-130-regulatory-update/
Help for Today. Hope for Tomorrow.
HDSA Statement on uniQure’s AMT-130 Regulatory Update 1